PubMed:27342131 / 0-356 JSONTXT

{"project":"sentences","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":201},"obj":"Sentence"},{"id":"TextSentencer_T2","span":{"begin":202,"end":318},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":201},"obj":"Sentence"},{"id":"T2","span":{"begin":202,"end":318},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The pecking order of skin Advanced Glycation Endproducts (AGEs) as long-term markers of glycemic damage and risk factors for micro- and subclinical macrovascular disease progression in Type 1 diabetes.\nTo date more than 20 glycation products were identified, of which ~15 in the insoluble human skin collagen fraction. The goal of this review is to streaml"}

{"project":"Glycosmos6-MAT","denotations":[{"id":"T1","span":{"begin":21,"end":25},"obj":"http://purl.obolibrary.org/obo/MAT_0000284"},{"id":"T2","span":{"begin":295,"end":299},"obj":"http://purl.obolibrary.org/obo/MAT_0000284"}],"text":"The pecking order of skin Advanced Glycation Endproducts (AGEs) as long-term markers of glycemic damage and risk factors for micro- and subclinical macrovascular disease progression in Type 1 diabetes.\nTo date more than 20 glycation products were identified, of which ~15 in the insoluble human skin collagen fraction. The goal of this review is to streaml"}

{"project":"GlyCosmos600-FMA","denotations":[{"id":"T1","span":{"begin":21,"end":25},"obj":"Body_part"},{"id":"T2","span":{"begin":295,"end":299},"obj":"Body_part"},{"id":"T3","span":{"begin":300,"end":308},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma7163"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma7163"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma63891"}],"text":"The pecking order of skin Advanced Glycation Endproducts (AGEs) as long-term markers of glycemic damage and risk factors for micro- and subclinical macrovascular disease progression in Type 1 diabetes.\nTo date more than 20 glycation products were identified, of which ~15 in the insoluble human skin collagen fraction. The goal of this review is to streaml"}

{"project":"GlyCosmos600-MAT","denotations":[{"id":"PD-MAT-B_T1","span":{"begin":21,"end":25},"obj":"http://purl.obolibrary.org/obo/MAT_0000284"},{"id":"PD-MAT-B_T2","span":{"begin":295,"end":299},"obj":"http://purl.obolibrary.org/obo/MAT_0000284"}],"text":"The pecking order of skin Advanced Glycation Endproducts (AGEs) as long-term markers of glycemic damage and risk factors for micro- and subclinical macrovascular disease progression in Type 1 diabetes.\nTo date more than 20 glycation products were identified, of which ~15 in the insoluble human skin collagen fraction. The goal of this review is to streaml"}

{"project":"GlyCosmos600-GlycoProteins","denotations":[{"id":"PD-GlycoProteins-B_T5","span":{"begin":300,"end":308},"obj":"https://acgg.asia/db/gpdb/id/GPDB0000044"},{"id":"PD-GlycoProteins-B_T8","span":{"begin":300,"end":308},"obj":"https://acgg.asia/db/gpdb/id/GPDB0000046"},{"id":"PD-GlycoProteins-B_T11","span":{"begin":300,"end":308},"obj":"https://acgg.asia/db/gpdb/id/GPDB0000049"},{"id":"PD-GlycoProteins-B_T14","span":{"begin":300,"end":308},"obj":"https://acgg.asia/db/gpdb/id/GPDB0000050"},{"id":"PD-GlycoProteins-B_T17","span":{"begin":300,"end":308},"obj":"https://acgg.asia/db/gpdb/id/GPDB0000051"},{"id":"PD-GlycoProteins-B_T20","span":{"begin":300,"end":308},"obj":"https://acgg.asia/db/gpdb/id/GPDB0000052"},{"id":"PD-GlycoProteins-B_T23","span":{"begin":300,"end":308},"obj":"https://acgg.asia/db/gpdb/id/GPDB0000053"},{"id":"PD-GlycoProteins-B_T26","span":{"begin":300,"end":308},"obj":"https://acgg.asia/db/gpdb/id/GPDB0000058"},{"id":"PD-GlycoProteins-B_T29","span":{"begin":300,"end":308},"obj":"https://acgg.asia/db/gpdb/id/GPDB0000060"},{"id":"PD-GlycoProteins-B_T32","span":{"begin":300,"end":308},"obj":"https://acgg.asia/db/gpdb/id/GPDB0000061"},{"id":"PD-GlycoProteins-B_T35","span":{"begin":300,"end":308},"obj":"https://acgg.asia/db/gpdb/id/GPDB0000063"},{"id":"PD-GlycoProteins-B_T38","span":{"begin":300,"end":308},"obj":"https://acgg.asia/db/gpdb/id/GPDB0001086"},{"id":"PD-GlycoProteins-B_T41","span":{"begin":300,"end":308},"obj":"https://acgg.asia/db/gpdb/id/GPDB0001092"},{"id":"PD-GlycoProteins-B_T44","span":{"begin":300,"end":308},"obj":"https://acgg.asia/db/gpdb/id/GPDB0001095"}],"text":"The pecking order of skin Advanced Glycation Endproducts (AGEs) as long-term markers of glycemic damage and risk factors for micro- and subclinical macrovascular disease progression in Type 1 diabetes.\nTo date more than 20 glycation products were identified, of which ~15 in the insoluble human skin collagen fraction. The goal of this review is to streaml"}

{"project":"pubmed-enju-pas","denotations":[{"id":"EnjuParser_T0","span":{"begin":0,"end":3},"obj":"DT"},{"id":"EnjuParser_T1","span":{"begin":4,"end":11},"obj":"VBG"},{"id":"EnjuParser_T2","span":{"begin":12,"end":17},"obj":"NN"},{"id":"EnjuParser_T3","span":{"begin":18,"end":20},"obj":"IN"},{"id":"EnjuParser_T4","span":{"begin":21,"end":25},"obj":"NN"},{"id":"EnjuParser_T5","span":{"begin":26,"end":34},"obj":"VBN"},{"id":"EnjuParser_T6","span":{"begin":35,"end":44},"obj":"NN"},{"id":"EnjuParser_T7","span":{"begin":45,"end":56},"obj":"NNS"},{"id":"EnjuParser_T8","span":{"begin":57,"end":58},"obj":"-LRB-"},{"id":"EnjuParser_T9","span":{"begin":58,"end":62},"obj":"NNS"},{"id":"EnjuParser_T10","span":{"begin":62,"end":63},"obj":"-RRB-"},{"id":"EnjuParser_T11","span":{"begin":64,"end":66},"obj":"IN"},{"id":"EnjuParser_T12","span":{"begin":67,"end":76},"obj":"JJ"},{"id":"EnjuParser_T13","span":{"begin":77,"end":84},"obj":"NNS"},{"id":"EnjuParser_T14","span":{"begin":85,"end":87},"obj":"IN"},{"id":"EnjuParser_T15","span":{"begin":88,"end":96},"obj":"JJ"},{"id":"EnjuParser_T16","span":{"begin":97,"end":103},"obj":"NN"},{"id":"EnjuParser_T17","span":{"begin":104,"end":107},"obj":"CC"},{"id":"EnjuParser_T18","span":{"begin":108,"end":112},"obj":"NN"},{"id":"EnjuParser_T19","span":{"begin":113,"end":120},"obj":"NNS"},{"id":"EnjuParser_T20","span":{"begin":121,"end":124},"obj":"IN"},{"id":"EnjuParser_T21","span":{"begin":125,"end":131},"obj":"NN"},{"id":"EnjuParser_T22","span":{"begin":132,"end":135},"obj":"CC"},{"id":"EnjuParser_T23","span":{"begin":136,"end":147},"obj":"JJ"},{"id":"EnjuParser_T24","span":{"begin":148,"end":161},"obj":"JJ"},{"id":"EnjuParser_T25","span":{"begin":162,"end":169},"obj":"NN"},{"id":"EnjuParser_T26","span":{"begin":170,"end":181},"obj":"NN"},{"id":"EnjuParser_T27","span":{"begin":182,"end":184},"obj":"IN"},{"id":"EnjuParser_T28","span":{"begin":185,"end":189},"obj":"NN"},{"id":"EnjuParser_T29","span":{"begin":190,"end":191},"obj":"CD"},{"id":"EnjuParser_T30","span":{"begin":192,"end":200},"obj":"NN"},{"id":"EnjuParser_T31","span":{"begin":202,"end":204},"obj":"TO"},{"id":"EnjuParser_T32","span":{"begin":205,"end":209},"obj":"NN"},{"id":"EnjuParser_T33","span":{"begin":210,"end":214},"obj":"JJR"},{"id":"EnjuParser_T34","span":{"begin":215,"end":219},"obj":"IN"},{"id":"EnjuParser_T35","span":{"begin":220,"end":222},"obj":"CD"},{"id":"EnjuParser_T36","span":{"begin":223,"end":232},"obj":"NN"},{"id":"EnjuParser_T37","span":{"begin":233,"end":241},"obj":"NNS"},{"id":"EnjuParser_T38","span":{"begin":242,"end":246},"obj":"VBD"},{"id":"EnjuParser_T39","span":{"begin":247,"end":257},"obj":"VBN"},{"id":"EnjuParser_T40","span":{"begin":257,"end":258},"obj":"-COMMA-"},{"id":"EnjuParser_T41","span":{"begin":259,"end":261},"obj":"IN"},{"id":"EnjuParser_T42","span":{"begin":262,"end":267},"obj":"WDT"},{"id":"EnjuParser_T43","span":{"begin":268,"end":271},"obj":"CD"},{"id":"EnjuParser_T44","span":{"begin":272,"end":274},"obj":"IN"},{"id":"EnjuParser_T45","span":{"begin":275,"end":278},"obj":"DT"},{"id":"EnjuParser_T46","span":{"begin":279,"end":288},"obj":"JJ"},{"id":"EnjuParser_T47","span":{"begin":289,"end":294},"obj":"JJ"},{"id":"EnjuParser_T48","span":{"begin":295,"end":299},"obj":"NN"},{"id":"EnjuParser_T49","span":{"begin":300,"end":308},"obj":"NN"},{"id":"EnjuParser_T50","span":{"begin":309,"end":317},"obj":"NN"},{"id":"EnjuParser_T51","span":{"begin":319,"end":322},"obj":"DT"},{"id":"EnjuParser_T52","span":{"begin":323,"end":327},"obj":"NN"},{"id":"EnjuParser_T53","span":{"begin":328,"end":330},"obj":"IN"},{"id":"EnjuParser_T54","span":{"begin":331,"end":335},"obj":"DT"},{"id":"EnjuParser_T55","span":{"begin":336,"end":342},"obj":"NN"},{"id":"EnjuParser_T56","span":{"begin":343,"end":345},"obj":"VBZ"},{"id":"EnjuParser_T57","span":{"begin":346,"end":348},"obj":"TO"}],"relations":[{"id":"EnjuParser_R0","pred":"arg1Of","subj":"EnjuParser_T2","obj":"EnjuParser_T0"},{"id":"EnjuParser_R1","pred":"arg1Of","subj":"EnjuParser_T2","obj":"EnjuParser_T1"},{"id":"EnjuParser_R2","pred":"arg1Of","subj":"EnjuParser_T2","obj":"EnjuParser_T3"},{"id":"EnjuParser_R3","pred":"arg2Of","subj":"EnjuParser_T4","obj":"EnjuParser_T3"},{"id":"EnjuParser_R4","pred":"arg1Of","subj":"EnjuParser_T2","obj":"EnjuParser_T5"},{"id":"EnjuParser_R5","pred":"arg2Of","subj":"EnjuParser_T7","obj":"EnjuParser_T5"},{"id":"EnjuParser_R6","pred":"arg1Of","subj":"EnjuParser_T7","obj":"EnjuParser_T6"},{"id":"EnjuParser_R7","pred":"arg1Of","subj":"EnjuParser_T7","obj":"EnjuParser_T8"},{"id":"EnjuParser_R8","pred":"arg2Of","subj":"EnjuParser_T9","obj":"EnjuParser_T8"},{"id":"EnjuParser_R9","pred":"arg3Of","subj":"EnjuParser_T10","obj":"EnjuParser_T8"},{"id":"EnjuParser_R10","pred":"arg1Of","subj":"EnjuParser_T5","obj":"EnjuParser_T11"},{"id":"EnjuParser_R11","pred":"arg2Of","subj":"EnjuParser_T13","obj":"EnjuParser_T11"},{"id":"EnjuParser_R12","pred":"arg1Of","subj":"EnjuParser_T13","obj":"EnjuParser_T12"},{"id":"EnjuParser_R13","pred":"arg1Of","subj":"EnjuParser_T13","obj":"EnjuParser_T14"},{"id":"EnjuParser_R14","pred":"arg2Of","subj":"EnjuParser_T22","obj":"EnjuParser_T14"},{"id":"EnjuParser_R15","pred":"arg1Of","subj":"EnjuParser_T16","obj":"EnjuParser_T15"},{"id":"EnjuParser_R16","pred":"arg1Of","subj":"EnjuParser_T16","obj":"EnjuParser_T17"},{"id":"EnjuParser_R17","pred":"arg2Of","subj":"EnjuParser_T19","obj":"EnjuParser_T17"},{"id":"EnjuParser_R18","pred":"arg1Of","subj":"EnjuParser_T19","obj":"EnjuParser_T18"},{"id":"EnjuParser_R19","pred":"arg1Of","subj":"EnjuParser_T17","obj":"EnjuParser_T20"},{"id":"EnjuParser_R20","pred":"arg2Of","subj":"EnjuParser_T21","obj":"EnjuParser_T20"},{"id":"EnjuParser_R21","pred":"arg1Of","subj":"EnjuParser_T17","obj":"EnjuParser_T22"},{"id":"EnjuParser_R22","pred":"arg2Of","subj":"EnjuParser_T26","obj":"EnjuParser_T22"},{"id":"EnjuParser_R23","pred":"arg1Of","subj":"EnjuParser_T26","obj":"EnjuParser_T23"},{"id":"EnjuParser_R24","pred":"arg1Of","subj":"EnjuParser_T26","obj":"EnjuParser_T24"},{"id":"EnjuParser_R25","pred":"arg1Of","subj":"EnjuParser_T26","obj":"EnjuParser_T25"},{"id":"EnjuParser_R26","pred":"arg1Of","subj":"EnjuParser_T22","obj":"EnjuParser_T27"},{"id":"EnjuParser_R27","pred":"arg2Of","subj":"EnjuParser_T30","obj":"EnjuParser_T27"},{"id":"EnjuParser_R28","pred":"arg1Of","subj":"EnjuParser_T30","obj":"EnjuParser_T28"},{"id":"EnjuParser_R29","pred":"arg1Of","subj":"EnjuParser_T30","obj":"EnjuParser_T29"},{"id":"EnjuParser_R30","pred":"arg1Of","subj":"EnjuParser_T39","obj":"EnjuParser_T31"},{"id":"EnjuParser_R31","pred":"arg2Of","subj":"EnjuParser_T32","obj":"EnjuParser_T31"},{"id":"EnjuParser_R32","pred":"arg1Of","subj":"EnjuParser_T37","obj":"EnjuParser_T33"},{"id":"EnjuParser_R33","pred":"arg1Of","subj":"EnjuParser_T33","obj":"EnjuParser_T34"},{"id":"EnjuParser_R34","pred":"arg2Of","subj":"EnjuParser_T35","obj":"EnjuParser_T34"},{"id":"EnjuParser_R35","pred":"arg1Of","subj":"EnjuParser_T37","obj":"EnjuParser_T36"},{"id":"EnjuParser_R36","pred":"arg1Of","subj":"EnjuParser_T37","obj":"EnjuParser_T38"},{"id":"EnjuParser_R37","pred":"arg2Of","subj":"EnjuParser_T39","obj":"EnjuParser_T38"},{"id":"EnjuParser_R38","pred":"arg2Of","subj":"EnjuParser_T37","obj":"EnjuParser_T39"},{"id":"EnjuParser_R39","pred":"arg1Of","subj":"EnjuParser_T39","obj":"EnjuParser_T40"},{"id":"EnjuParser_R40","pred":"arg1Of","subj":"EnjuParser_T39","obj":"EnjuParser_T41"},{"id":"EnjuParser_R41","pred":"arg2Of","subj":"EnjuParser_T43","obj":"EnjuParser_T41"},{"id":"EnjuParser_R42","pred":"arg1Of","subj":"EnjuParser_T43","obj":"EnjuParser_T42"},{"id":"EnjuParser_R43","pred":"arg1Of","subj":"EnjuParser_T43","obj":"EnjuParser_T44"},{"id":"EnjuParser_R44","pred":"arg2Of","subj":"EnjuParser_T50","obj":"EnjuParser_T44"},{"id":"EnjuParser_R45","pred":"arg1Of","subj":"EnjuParser_T50","obj":"EnjuParser_T45"},{"id":"EnjuParser_R46","pred":"arg1Of","subj":"EnjuParser_T50","obj":"EnjuParser_T46"},{"id":"EnjuParser_R47","pred":"arg1Of","subj":"EnjuParser_T50","obj":"EnjuParser_T47"},{"id":"EnjuParser_R48","pred":"arg1Of","subj":"EnjuParser_T50","obj":"EnjuParser_T48"},{"id":"EnjuParser_R49","pred":"arg1Of","subj":"EnjuParser_T50","obj":"EnjuParser_T49"},{"id":"EnjuParser_R50","pred":"arg1Of","subj":"EnjuParser_T52","obj":"EnjuParser_T51"},{"id":"EnjuParser_R51","pred":"arg1Of","subj":"EnjuParser_T52","obj":"EnjuParser_T53"},{"id":"EnjuParser_R52","pred":"arg2Of","subj":"EnjuParser_T55","obj":"EnjuParser_T53"},{"id":"EnjuParser_R53","pred":"arg1Of","subj":"EnjuParser_T55","obj":"EnjuParser_T54"},{"id":"EnjuParser_R54","pred":"arg1Of","subj":"EnjuParser_T52","obj":"EnjuParser_T56"}],"namespaces":[{"prefix":"_base","uri":"http://kmcs.nii.ac.jp/enju/"}],"text":"The pecking order of skin Advanced Glycation Endproducts (AGEs) as long-term markers of glycemic damage and risk factors for micro- and subclinical macrovascular disease progression in Type 1 diabetes.\nTo date more than 20 glycation products were identified, of which ~15 in the insoluble human skin collagen fraction. The goal of this review is to streaml"}

{"project":"mondo_disease","denotations":[{"id":"T1","span":{"begin":185,"end":200},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0005147"}],"text":"The pecking order of skin Advanced Glycation Endproducts (AGEs) as long-term markers of glycemic damage and risk factors for micro- and subclinical macrovascular disease progression in Type 1 diabetes.\nTo date more than 20 glycation products were identified, of which ~15 in the insoluble human skin collagen fraction. The goal of this review is to streaml"}

{"project":"HP-phenotype","denotations":[{"id":"T1","span":{"begin":185,"end":200},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"HP:0100651"}],"namespaces":[{"prefix":"HP","uri":"http://purl.obolibrary.org/obo/HP_"}],"text":"The pecking order of skin Advanced Glycation Endproducts (AGEs) as long-term markers of glycemic damage and risk factors for micro- and subclinical macrovascular disease progression in Type 1 diabetes.\nTo date more than 20 glycation products were identified, of which ~15 in the insoluble human skin collagen fraction. The goal of this review is to streaml"}

{"project":"NCBITAXON","denotations":[{"id":"T1","span":{"begin":289,"end":294},"obj":"OrganismTaxon"}],"attributes":[{"id":"A1","pred":"db_id","subj":"T1","obj":"9606"}],"text":"The pecking order of skin Advanced Glycation Endproducts (AGEs) as long-term markers of glycemic damage and risk factors for micro- and subclinical macrovascular disease progression in Type 1 diabetes.\nTo date more than 20 glycation products were identified, of which ~15 in the insoluble human skin collagen fraction. The goal of this review is to streaml"}

{"project":"Anatomy-MAT","denotations":[{"id":"T1","span":{"begin":21,"end":25},"obj":"Body_part"},{"id":"T2","span":{"begin":295,"end":299},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"mat_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MAT_0000284"},{"id":"A2","pred":"mat_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MAT_0000284"}],"text":"The pecking order of skin Advanced Glycation Endproducts (AGEs) as long-term markers of glycemic damage and risk factors for micro- and subclinical macrovascular disease progression in Type 1 diabetes.\nTo date more than 20 glycation products were identified, of which ~15 in the insoluble human skin collagen fraction. The goal of this review is to streaml"}

{"project":"Anatomy-UBERON","denotations":[{"id":"T1","span":{"begin":21,"end":25},"obj":"Body_part"},{"id":"T5","span":{"begin":295,"end":299},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0000014"},{"id":"A2","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0001003"},{"id":"A3","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0002097"},{"id":"A4","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0002199"},{"id":"A5","pred":"uberon_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/UBERON_0000014"},{"id":"A6","pred":"uberon_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/UBERON_0001003"},{"id":"A7","pred":"uberon_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/UBERON_0002097"},{"id":"A8","pred":"uberon_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/UBERON_0002199"}],"text":"The pecking order of skin Advanced Glycation Endproducts (AGEs) as long-term markers of glycemic damage and risk factors for micro- and subclinical macrovascular disease progression in Type 1 diabetes.\nTo date more than 20 glycation products were identified, of which ~15 in the insoluble human skin collagen fraction. The goal of this review is to streaml"}